Table 2 Association between risk factors and incidence of linezolid-associated thrombocytopenia.

From: Renal replacement therapy and concurrent fluconazole therapy increase linezolid-related thrombocytopenia among adult patients

Variables

Crude model

Main model

OR

95% CI

P-value

OR

95% CI

P-value

Age

1.018

0.992–1.045

0.1851

–

–

–

Male

2.296

1.021–5.166

0.0445

2.210

0.829–5.890

0.1127

BMI

0.998

0.926–1.075

0.9512

–

–

–

Linezolid treatment duration

1.057

0.992–1.125

0.0861

1.071

1.000–1.146

0.0506

Routes of linezolid

IV

3.427

1.239–9.480

0.0176

2.950

0.884–9.847

0.0786

Both IV and oral

3.427

0.731–16.080

0.1183

1.314

0.187–9.236

0.7840

Baseline platelet count

1.001

0.998–1.004

0.5900

–

–

–

ICU admission

1.623

0.730–3.611

0.2349

–

–

–

Renal replacement therapy

4.721

1.593–13.993

0.0051

4.773

1.390–16.389

0.0130

Hypertension

1.200

0.515–2.795

0.6726

-

-

-

Diabetes mellitus

2.882

1.253–6.628

0.0128

1.698

0.635–4.544

0.2917

Liver diseases

1.395

0.456–4.273

0.5596

–

–

–

Cephalosporin

1.459

0.580–3.671

0.4218

–

–

–

Carbapenem

2.025

0.896–4.574

0.0897

1.056

0.397–2.813

0.9125

Fluconazole

2.428

1.033–5.708

0.0419

3.474

1.230–9.810

0.0187

Fluoroquinolone

1.128

0.472–2.695

0.7865

–

–

–

  1. Main model was adjusted for gender, treatment duration, routes of administration, renal replacement therapy, diabetes mellitus, concurrent carbapenem, and concurrent fluconazole therapy. BMI, body mass index; ICU, intensive care unit; IV, intravenous; CI, confidence interval.
Back to article page